Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...

Purple Biotech has entered a Phase II trial with its small molecule drug, NT219, focusing on patients with ...

Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug ...

Skin cancer is a common type of cancer that can occur anywhere on the body Read to find out about the least expected areas ...

CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reports fiscal year 2024 financial and operational ...

Opdivo-Qvantig had a non-inferior objective response rate compared to intravenous formulation in patients with locally ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...

Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...

Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...